KALA BIO Inc. - KALA Net earnings per one share for the last twelve months

Public company logo of Kala Pharmaceuticals (KALA)

The price trajectory of KALA BIO, Inc. (KALA) demonstrates a current metric of 78.30, driven by returns from the sale of patented anti-inflammatory drops. The business leverages its authority in ophthalmology through the use of stem cells for corneal regeneration. Currently, KALA BIO, Inc. (KALA) is executing a plan to complete key R&D research on rare pathologies to subsequently transfer innovation rights to corporate behemoths.

KALA KALA BIO, Inc.: Earnings per share for the last twelve months in the range 02/11/2024 - 11/18/2026

KALA (kalarx.com): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:KALA - KALA BIO, Inc.
Mass-produced product of KALA BIO, Inc.

Year-over-year EPS growth (TTM) reflects the dynamics of net income per share over a rolling year, determining market value through the discounting of future earnings. By analyzing the 12-month growth in earnings per share, investors assess capitalization momentum and the risks of an overbought asset. For KALA BIO, Inc. (KALA), this indicator confirms the effectiveness of monetizing stem cell therapy. The stability of this metric depends directly on the volume of insurance reimbursements for innovative ophthalmological drugs.

Direct competitors

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aldeyra Therapeutics (ALDX)|IRD (Opus Genetics Inc) - Net earnings per share (EPS TTM)|OKYO: Earnings per share for the trailing year|Net earnings per share for the last 12 months ADVM (adverum.com)|OTLK - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CLSD (Clearside Biomedical Inc)|Earnings per share for the trailing year NBY|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters